Briefs

Industry leaders to advance new predictive and therapeutic models for cardiovascular diseases

Burlington, MA - November 5, 2002 - AnVil, Inc. and Genomics Collaborative, Inc. (GCI) today unveiled the details of a new strategic alliance that will enable AnVil and GCI to pursue opportunities in marketing clinical data analyses to improve treatment of serious diseases.

The agreement calls for AnVil to work with GCI in analyzing cardiovascular clinical data from GCI's Global Repository�, a proprietary database of properly consented, well annotated DNA, Tissue, and serum samples collected from more than 115,000 individuals, to better drive ongoing molecular and clinical research efforts. Both companies will leverage the knowledge gained from these analyses through marketing the results to pharmaceutical, biotechnology, and clinical research organizations (CROs) with the objective of facilitating new technological advances for treating patients with cardiovascular diseases.

See www.anvilinfo.com for more information.